Bryan Ridgell - Geron Senior Staff
| GERN Stock | USD 1.41 0.07 5.22% |
Executive
Bryan Ridgell is Senior Staff of Geron
| Address | 919 East Hillsdale Boulevard, Foster City, CA, United States, 94404 |
| Phone | 650 473 7700 |
| Web | https://www.geron.com |
Geron Management Efficiency
The company has return on total asset (ROA) of (0.0779) % which means that it has lost $0.0779 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2957) %, meaning that it created substantial loss on money invested by shareholders. Geron's management efficiency ratios could be used to measure how well Geron manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of January 2026, Return On Tangible Assets is likely to drop to -0.28. In addition to that, Return On Capital Employed is likely to drop to -0.42. At this time, Geron's Total Assets are very stable compared to the past year. As of the 22nd of January 2026, Non Current Assets Total is likely to grow to about 124.1 M, while Other Current Assets are likely to drop about 3.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Bhavesh MBA | Tyra Biosciences | 60 | |
| Daron Evans | Rezolute | 50 | |
| Mika MD | Vir Biotechnology | 62 | |
| Brent Rice | ArriVent BioPharma Common | 60 | |
| Alexander Santini | Arvinas | 66 | |
| Phillip MD | Vir Biotechnology | 48 | |
| Erin OBoyle | Rezolute | N/A | |
| Kendra Wergin | Valneva SE ADR | 40 | |
| Toby Medaris | Vir Biotechnology | N/A | |
| Alan Fuhrman | Tyra Biosciences | 67 | |
| Toby MSc | Vir Biotechnology | N/A | |
| David Murphy | LENZ Therapeutics | N/A | |
| Hanneke Schuitemaker | Valneva SE ADR | 62 | |
| Peter Clarke | Savara Inc | 65 | |
| Sarah Honig | Tyra Biosciences | N/A | |
| Dandan Dong | ArriVent BioPharma Common | 39 | |
| Christopher Sarchi | Replimune Group | 56 | |
| Liz Pagano | Tyra Biosciences | N/A | |
| Gopal MBBS | Rezolute | N/A | |
| Christian Taucher | Valneva SE ADR | N/A | |
| Marvin Garrett | LENZ Therapeutics | 74 | |
Management Performance
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.0779 |
Geron Leadership Team
Elected by the shareholders, the Geron's board of directors comprises two types of representatives: Geron inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Geron. The board's role is to monitor Geron's management team and ensure that shareholders' interests are well served. Geron's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Geron's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Faye MD, Executive Officer | ||
| Joseph MD, Executive Development | ||
| Dawn Bir, Interim Director | ||
| Dawn CFA, Senior Affairs | ||
| Stephen JD, Chief VP | ||
| Shanthakumar Tyavanagimatt, Senior Officer | ||
| Andrew Grethlein, Executive VP of Devel. and Technical Operations | ||
| Aron Feingold, Vice Communications | ||
| John MD, President Board | ||
| James MBA, Executive Officer | ||
| Michelle Robertson, CFO, VP | ||
| Ahmed ElNawawi, Executive Officer | ||
| Anil Kapur, Executive Officer | ||
| Harout Semerjian, President CEO | ||
| Edward Koval, Executive Officer | ||
| Shannon Odam, Vice President - Human Resources | ||
| Melissa Behrs, Executive Vice President - Portfolio and Alliance Management | ||
| Olivia Bloom, CFO, Executive VP of Fin. and Treasurer | ||
| Bryan Ridgell, Senior Staff | ||
| Scott Samuels, Chief VP |
Geron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Geron a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.0779 | ||||
| Profit Margin | (0.44) % | ||||
| Operating Margin | (0.29) % | ||||
| Current Valuation | 596.78 M | ||||
| Shares Outstanding | 638.36 M | ||||
| Shares Owned By Insiders | 0.09 % | ||||
| Shares Owned By Institutions | 81.55 % | ||||
| Number Of Shares Shorted | 71.26 M | ||||
| Price To Earning | (12.48) X |
Pair Trading with Geron
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Geron position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Geron will appreciate offsetting losses from the drop in the long position's value.Moving against Geron Stock
| 0.73 | PYC | Physiomics Plc | PairCorr |
| 0.59 | CMB | Cambium Bio | PairCorr |
| 0.51 | AVH | Avita Medical | PairCorr |
| 0.46 | DRMA | Dermata Therapeutics | PairCorr |
| 0.44 | DTIL | Precision BioSciences | PairCorr |
The ability to find closely correlated positions to Geron could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Geron when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Geron - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Geron to buy it.
The correlation of Geron is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Geron moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Geron moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Geron can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Geron. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.12) | Revenue Per Share | Quarterly Revenue Growth 0.671 | Return On Assets | Return On Equity |
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.